NSI-189 is a non-natural nootropic in clinical trial developed by Neuralstem Inc.
The purpose of NSI-189 is to treat depression and cognitive decline.
A few days ago Neuralstem announced that clinical trial Phase 2 is being finished. Test results will be announced very soon. Research suggests that NSI-189 works by promoting growth of synapses and neurogenesis in the hippocampus.
By doing various scans, earlier data suggests that NSI-189 intake grows the hippocampus up to 20%. That’s a whole lot of brain and this is very promising!
We look forward to Neuralstem’s upcoming final results for the Phase 2 trial.